CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Concert Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Concert Pharmaceuticals Inc
Suite 500, 99 Hayden Avenue
Phone: (781) 860-0045p:781 860-0045 LEXINGTON, MA  02421  United States Fax: (302) 636-5454f:302 636-5454
This company was Merged or Acquired on 3/6/2023.
This company ceased filing statements with the SEC on 3/16/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The Company is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The Company is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board, Co-founder Richard H.Aldrich 67 5/1/2006 5/1/2006
President, Chief Executive Officer, Co-Founder, Director Roger D.Tung 62 4/1/2006 4/1/2006
Chief Financial Officer Marc A.Becker 50 12/27/2019 1/4/2018
7 additional Officers and Directors records available in full report.

Business Names
Business Name
CNCE
Concert Pharma Ireland Limited
Concert Pharma U.K. Ltd
Concert Pharmaceuticals Securities Corporation

General Information
Number of Employees: 64 (As of 12/31/2021)
Outstanding Shares: 47,938,188 (As of 11/1/2022)
Shareholders: 12
Stock Exchange: NASD
Federal Tax Id: 204839882
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 12, 2024